Last reviewed · How we verify
D930
D930 is an investigational drug in phase 3 development by Chong Kun Dang Pharmaceutical with an undisclosed mechanism of action.
At a glance
| Generic name | D930 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Limited public information is available regarding D930's specific molecular mechanism. As a phase 3 candidate from Chong Kun Dang Pharmaceutical, it has progressed through early clinical testing, but detailed mechanistic data has not been widely disclosed in accessible pharmaceutical databases or literature.
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate Drug-drug Interaction, Safety and Tolerability in Case of the Co-administration of D565 and D930 (PHASE1)
- A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 (PHASE3)
- The Pharmacokinetics of D565 and the Drug Effect of D565 on Pharmacokinetic Characteristics of D930 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- D930 CI brief — competitive landscape report
- D930 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI